Obamacare Wonks Cash In on Health Care Law
The New York Times had an important story Tuesday on the ways in which former congressional and White House staffers are profiting from the Affordable Care Act they helped write and pass.had an important story Tuesday on the ways in which former congressional and White House staffers are profiting from the Affordable Care Act they helped write and pass.
Judging by the story, a lot of those passing through Washington’s revolving door end up working for the health industry — that’s insurance companies, pharmaceutical firms, health care providers, device makers and so on — which now spends more on lobbying than even the big banks.
There are exceptions to the rule, as the Times reports:
Many of the former health care officials are lawyers or lobbyists, though not all. Nancy-Ann DeParle, Mr. Obama’s former “health czar” and later his deputy chief of staff, now guides health care investments as a partner in a new private equity firm, Consonance Capital, with colleagues from her pre-White House days. Bob Kocher, a doctor, management consultant and former member of Mr. Obama’s economics team, is a California venture capitalist, helping finance health start-ups.
‘
In any event, profit seems to be the chief motive. It’s a pity investors and corporations have cornered the market on these former public servants, if only because there are now millions of Americans who have to comply with the law and would probably welcome a little insight from some insiders.
— Posted by Peter Z. Scheer
Your support is crucial…With an uncertain future and a new administration casting doubt on press freedoms, the danger is clear: The truth is at risk.
Now is the time to give. Your tax-deductible support allows us to dig deeper, delivering fearless investigative reporting and analysis that exposes what’s really happening — without compromise.
Stand with our courageous journalists. Donate today to protect a free press, uphold democracy and unearth untold stories.
You need to be a supporter to comment.
There are currently no responses to this article.
Be the first to respond.